Title:
USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES
Document Type and Number:
WIPO Patent Application WO/2022/002160
Kind Code:
A1
Abstract:
Provided in the present invention is the use of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in a product for treating multiple diseases. The PCSK9 inhibitor is a PCSK9 small molecule compound, or a PCSK9 interfering RNA, or a PCSK9 monoclonal antibody, or a PCSK9 mimetic peptide, or a PCSK9 mimetic antibody protein, or a PCSK9 antisense oligonucleotide or a PCSK9 vaccine.
More Like This:
Inventors:
CHEN MIN (CN)
WANG YICHEN (CN)
WANG YICHEN (CN)
Application Number:
PCT/CN2021/103749
Publication Date:
January 06, 2022
Filing Date:
June 30, 2021
Export Citation:
Assignee:
CHEN MIN (CN)
International Classes:
A61K31/437; A61K39/395; A61P17/00; A61P17/02; A61P17/10; A61P17/14; C12N15/11
Domestic Patent References:
| WO2009148605A2 | 2009-12-10 | |||
| WO2019236528A1 | 2019-12-12 |
Foreign References:
| US20180312607A1 | 2018-11-01 | |||
| CN108066763A | 2018-05-25 | |||
| TW201400464A | 2014-01-01 | |||
| CN106822864A | 2017-06-13 |
Other References:
NATHALIE BERGERON, BINH AN P. PHAN, YUNCHEN DING, ALEYNA FONG, RONALD M. KRAUSS: "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition : A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk", CIRCULATION, AMERICAN HEART ASSOCIATION, US, vol. 132, no. 17, 27 October 2015 (2015-10-27), US , pages 1648 - 1666, XP055664366, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.115.016080
Attorney, Agent or Firm:
BEIJING ZHI CHENG HAN FANG IP AGENCY CO., LTD. (CN)
Download PDF:
Previous Patent: MASTER-SLAVE MOTION CONTROL METHOD, ROBOT SYSTEM, DEVICE, AND STORAGE MEDIUM
Next Patent: POSITIVE-PRESSURE RESPIRATOR
Next Patent: POSITIVE-PRESSURE RESPIRATOR